Keller P, Morrison O, Vassell R, Weiss C
J Virol. 2018; 92(16).
PMID: 29875245
PMC: 6069199.
DOI: 10.1128/JVI.00583-18.
Pollara J, Bonsignori M, Moody M, Liu P, Alam S, Hwang K
J Virol. 2014; 88(14):7715-26.
PMID: 24807721
PMC: 4097802.
DOI: 10.1128/JVI.00156-14.
Tong T, Osawa K, Robinson J, Crooks E, Binley J
J Virol. 2013; 87(16):9233-49.
PMID: 23740975
PMC: 3754051.
DOI: 10.1128/JVI.01145-13.
Mancini N, Diotti R, Perotti M, Sautto G, Clementi N, Nitti G
PLoS One. 2009; 4(12):e8254.
PMID: 20011511
PMC: 2785886.
DOI: 10.1371/journal.pone.0008254.
Wu X, Sambor A, Nason M, Yang Z, Wu L, Zolla-Pazner S
Virology. 2008; 380(2):285-95.
PMID: 18804254
PMC: 3739291.
DOI: 10.1016/j.virol.2008.07.007.
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
Pantophlet R, Wilson I, Burton D
J Virol. 2003; 77(10):5889-901.
PMID: 12719582
PMC: 154011.
DOI: 10.1128/jvi.77.10.5889-5901.2003.
Synergy determination issues.
Chou T
J Virol. 2002; 76(20):10577; author reply 10578.
PMID: 12239339
PMC: 136565.
DOI: 10.1128/jvi.76.20.10577-10578.2002.
Molecular determinants of the human antibody response to HIV-1: implications for disease control.
Viau M, Zouali M
J Clin Immunol. 2002; 21(6):410-9.
PMID: 11811786
DOI: 10.1023/a:1013125726870.
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F, Nadas A, Gorny M, Zolla-Pazner S
J Virol. 2001; 75(19):9177-86.
PMID: 11533181
PMC: 114486.
DOI: 10.1128/JVI.75.19.9177-9186.2001.
Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
Li A, Katinger H, Posner M, Cavacini L, Zolla-Pazner S, Gorny M
J Virol. 1998; 72(4):3235-40.
PMID: 9525650
PMC: 109792.
DOI: 10.1128/JVI.72.4.3235-3240.1998.
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
Mascola J, Louder M, Vancott T, Sapan C, Lambert J, Muenz L
J Virol. 1997; 71(10):7198-206.
PMID: 9311792
PMC: 192059.
DOI: 10.1128/JVI.71.10.7198-7206.1997.
Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
Pinter A, Honnen W, Tilley S
J Virol. 1996; 70(7):4466-73.
PMID: 8676471
PMC: 190381.
DOI: 10.1128/JVI.70.7.4466-4473.1996.
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.
Moore J, Sodroski J
J Virol. 1996; 70(3):1863-72.
PMID: 8627711
PMC: 190014.
DOI: 10.1128/JVI.70.3.1863-1872.1996.
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N
J Virol. 1996; 70(2):1100-8.
PMID: 8551569
PMC: 189917.
DOI: 10.1128/JVI.70.2.1100-1108.1996.
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical....
Montefiori D, Graham B, Zhou J, Bucco R, Schwartz D, Cavacini L
J Clin Invest. 1993; 92(2):840-7.
PMID: 8349820
PMC: 294922.
DOI: 10.1172/JCI116658.
Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
Burkly L, Mulrey N, Blumenthal R, Dimitrov D
J Virol. 1995; 69(7):4267-73.
PMID: 7769687
PMC: 189165.
DOI: 10.1128/JVI.69.7.4267-4273.1995.
Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.
Pinter A, Honnen W, Tilley S
J Virol. 1993; 67(9):5692-7.
PMID: 7688827
PMC: 237978.
DOI: 10.1128/JVI.67.9.5692-5697.1993.
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
Thali M, Moore J, Furman C, Charles M, Ho D, Robinson J
J Virol. 1993; 67(7):3978-88.
PMID: 7685405
PMC: 237765.
DOI: 10.1128/JVI.67.7.3978-3988.1993.
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
Laal S, Burda S, Gorny M, Karwowska S, Buchbinder A, Zolla-Pazner S
J Virol. 1994; 68(6):4001-8.
PMID: 7514683
PMC: 236906.
DOI: 10.1128/JVI.68.6.4001-4008.1994.
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R, Thali M, Tilley S, Pinter A, Posner M, Ho D
J Virol. 1992; 66(12):6997-7004.
PMID: 1279195
PMC: 240347.
DOI: 10.1128/JVI.66.12.6997-7004.1992.
